DBV Technologies S.A. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; the filing is an annual report, not a standalone fourth-quarter report. Financial amounts below are in U.S. dollars unless noted. The company is a clinical-stage biopharmaceutical developer with no product sales, focused principally on its Viaskin epicutaneous immunotherapy platform.
Financial performance and position
| Metric | FY2020 | FY2019 |
|---|---|---|
| Product revenue | None | None |
| Operating income, mainly research tax credit and collaboration income | $11.3 million | $14.7 million |
| Research and development expense | $101.6 million | $115.1 million |
| Sales and marketing expense | $9.9 million | $21.6 million |
| General and administrative expense | $35.1 million | $49.1 million |
| Restructuring expense | $23.6 million | None |
| Net loss | $159.6 million | $172.0 million |
| Net loss per share | $2.95 | $4.65 |
| Operating cash flow | $(165.6) million | $(148.3) million |
| Cash and cash equivalents at year-end | $196.4 million | $193.3 million |
- Revenue and operating margins are not meaningful measures of commercial performance because DBV had no product sales; reported operating income comprises other income, principally a French research tax credit ($9.9 million in 2020) and collaboration income.
- Cash from financing was $149.5 million, primarily from equity issuance. Cash increased by $3.1 million overall, including a positive $22.0 million foreign-exchange effect.
- Total current assets were $207.4 million and current liabilities $52.7 million at year-end. The company reported no bank loans; financial debt consisted mainly of $1.3 million in conditional advances. Operating lease liabilities totaled $14.2 million.
- Accumulated deficit was $958.5 million. Management estimated available cash would fund operations into the second half of 2022, based on planned FDA work and restructuring savings.
Material changes and operating developments
- Net loss narrowed by about 7% as operating expenses fell, partly offset by $23.6 million of restructuring charges. R&D decreased 11.7%, sales and marketing 54.2%, and G&A 28.5% from 2019.
- Operating cash use increased to $165.6 million from $148.3 million, despite the lower net loss; the filing cites restructuring cash outflows and slower recovery of research tax credits.
- In June 2020, DBV began a global restructuring expected to eliminate more than 200 positions and leave a team of about 90. Full implementation was expected in the second half of 2021. Other research programs were scaled back to prioritize Viaskin Peanut.
- Cash balances were supported by a February–March 2020 global equity offering that generated $150.0 million in net proceeds. The share count increased during the year.
Outlook, risks, and unusual items
- United States: The FDA issued a Complete Response Letter in August 2020 and would not approve the Viaskin Peanut application in its current form. It raised patch adhesion and efficacy concerns, requested patch modifications, additional clinical data and CMC information, and recommended a six-month safety-and-adhesion study. The FDA did not raise safety concerns about the product. Management planned to submit study protocols for FDA review in Q2 2021; no approval or resubmission date was assured.
- European Union: The EMA validated the Viaskin Peanut marketing application in November 2020 for children ages 4–11, beginning formal review; validation is not approval.
- Clinical evidence: The pivotal PEPITES trial showed a statistically significant responder-rate difference, but did not meet its prespecified confidence-interval success criterion. The open-label PEOPLE extension reported increases in eliciting dose over three years; those results do not resolve the FDA’s patch-adhesion requirements.
- Funding and going concern: DBV expects continuing losses and will need additional capital. Management’s runway estimate depends on cost reductions and planned development activities; financing may dilute shareholders or be unavailable on acceptable terms. Financial statements were prepared on a going-concern basis.
- Other risks: COVID-19 delayed trial enrollment, including the Nestlé-collaboration MAG1C study; the company relies on third parties for manufacturing and clinical execution, and has limited commercial infrastructure. Competition includes FDA-approved oral peanut immunotherapy Palforzia. A securities class action concerning alleged statements from 2018–2020 was being defended; the company said it believed the claims lacked merit.
- Unusual accounting and controls: Restructuring included employee costs, lease effects and other charges; product-related inventory was written down to zero pending regulatory approval. Management reported effective disclosure controls and internal control over financial reporting as of year-end. The financial statement audit opinion was unqualified; the auditor did not opine on internal-control effectiveness.
Most important facts for investors to verify
- Actual cash burn, restructuring savings and whether the stated runway into the second half of 2022 remains achievable.
- Progress, timing, costs and results of the modified-patch adhesion, safety, allergen-uptake, human-factor and CMC work required by the FDA.
- EMA review outcome and any additional data or conditions requested for Viaskin Peanut.
- Enrollment and results for the toddler EPITOPE trial, and the effect of COVID-19 on MAG1C and other clinical work.
- Potential dilution from future fundraising, outstanding equity awards, and the status and financial exposure of the securities litigation.